Yongin, South Korea

Taekun An

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Bcworld Pharm. Co., Ltd.. Active years: 2015.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Taekun An: Innovator in Pharmaceutical Compositions

Introduction

Taekun An is a notable inventor based in Yongin, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions that enhance patient safety and compliance.

Latest Patents

Taekun An holds a patent for a pharmaceutical composition comprising metformin and rosuvastatin. This invention focuses on oral pharmaceutical compositions that combine metformin and rosuvastatin with sustained release carriers and/or excipients. The formulation aims to reduce the side effects associated with statins while improving safety and patient convenience through a one-per-day dosage. Additionally, it regulates an early effective blood concentration of the drug and maintains a steady level in vivo, making it advantageous for preventing and treating hyperlipidemia.

Career Highlights

Taekun An is currently associated with Bcworld Pharm. Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to improving drug formulations that benefit patients.

Collaborations

Some of his coworkers include Hearan Suh and Juhuen Choi, who contribute to the collaborative efforts in research and development at Bcworld Pharm. Co., Ltd.

Conclusion

Taekun An's innovative work in pharmaceutical compositions demonstrates his dedication to enhancing patient care through effective medication solutions. His contributions are vital in the ongoing efforts to improve health outcomes for individuals with hyperlipidemia.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…